2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-130368
    W-7 65595-90-6
    W-7 is a selective calmodulin antagonist. W-7 inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias.
    W-7
  • HY-130438
    EUK-118 186299-34-3 98%
    EUK-118 is an analog of EUK 8 and EUK 134 with reduced activity. EUK-118 exhibits superoxide dismutase (SOD) mimetic activity.
    EUK-118
  • HY-13047A
    rel-S-(+)-Mecamylamine hydrochloride 110691-49-1 98%
    rel-S-(+)-Mecamylamine hydrochloride is a known antihypertensive drug .
    rel-S-(+)-Mecamylamine hydrochloride
  • HY-130666
    Chlorambucyl-proline 81050-71-7 98%
    Chlorambucyl-proline is a chloroplatinyl amino acid derivative with inhibitory activity against bovine pulmonary vasoconstrictor enzyme. Chlorambucyl-proline reacts with the convertase in a 1:1 ratio, and the removal of its radiolabel indicates that the compound has an irreversible inhibitory effect on the enzyme activity. Chlorambucyl-proline binds to the aspartic acid or glutamic acid side chain of the enzyme by forming an ester bond, resulting in irreversible inactivation of the enzyme. The inactivation rate constant of chlororambucyl-proline increases in the pH range of 5-8, indicating that its effect on the enzyme activity is affected by the pH environment.
    Chlorambucyl-proline
  • HY-130673
    L-NABE 7672-27-7 98%
    L-NABE is a nitric oxide (NO) synthase inhibitor. L-NABE is also a potent endothelium dependent vasoconstrictor and inhibitor of relaxation.
    L-NABE
  • HY-131041
    Ned-K 2250019-90-8 98%
    Ned-K is a nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist. Ned-K is effective at dampening simulated ischaemia and reperfusion (sIR)-induced Ca2+ oscillations in cardiomyocytes.
    Ned-K
  • HY-131162
    Chymase 97501-92-3 98%
    Chymase is a protein-digester enzyme found primarily in mast cells (MC), fibroblasts, and vascular endothelial cells. Chymase is released into the extracellular stroma in the context of inflammatory signals, tissue injury and cellular stress. Chymase is also involved in angiotensin II (Ang II) production, which is used in cardiovascular disease studies.
    Chymase
  • HY-131279
    Olmesartan ethyl ester 144689-23-6 98%
    Olmesartan ethyl ester (compound 11) is an Olmesartan impurity. Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to in the high blood pressure study.
    Olmesartan ethyl ester
  • HY-131395
    N-Acetyl-Leukotriene E4 80115-95-3 98%
    N-Acetyl-Leukotriene E4 (N-Acetyl-LTE4) is a metabolite of Leukotriene E4 (LTE4) (HY-113465), which is detected in bile and urine. N-Acetyl-Leukotriene E4 produces a vasoconstriction in the mesenteric vessels which led to reduction of blood flow to the gut.
    N-Acetyl-Leukotriene E4
  • HY-131566
    Amiquinsin hydrochloride monohydrate 7125-70-4 98%
    Amiquinsin hydrochloride monohydrate is a compound with hypotensive activity. Amiquinsin hydrochloride monohydrate is metabolized in vivo, and the major metabolite is 4-amino-6,7-dimethoxy-3-quinolinol hydrochloride hydrate.
    Amiquinsin hydrochloride monohydrate
  • HY-131696
    11-deoxy Prostaglandin F1α 37785-98-1 98%
    11-deoxy Prostaglandin F1α (11-deoxy PGF1α) is an analog of prostaglandin F1α, exhibits side effects on intestines and causes the uterine contraction. 11-deoxy Prostaglandin F1α exhibits activity as vasopressor and bronchoconstrictor.
    11-deoxy Prostaglandin F1α
  • HY-131729
    16-Phenoxy tetranor Prostaglandin A2 51639-10-2 98%
    16-Phenoxy tetranor Prostaglandin A2 is a metabolite of uprostone and an analog of the antifertility hormone PGF2α.
    16-Phenoxy tetranor Prostaglandin A2
  • HY-131896
    FR144420 162626-99-5 98%
    FR144420 (NOR4) is an orally active nitric oxide (NO)-releasing agent with vasodilatory and antiplatelet effects. FR144420 induces cGMP-mediated vasodilation and inhibits platelet aggregation. FR144420 is promising for research of cardiovascular diseases, particularly angina pectoris and coronary artery spasm.
    FR144420
  • HY-13209S
    Ambrisentan-d10 1046116-27-1 98%
    Ambrisentan-d10 (BSF 208075-d10; LU 208075-d10) is the deuterium labled Ambrisentan (HY-13209). Ambrisentan is a selective ET type A receptor (ETAR) antagonist.
    Ambrisentan-d10
  • HY-132190
    Hexanolamino PAF C-16 137566-83-7 98%
    Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca2+-dependent and -independent pathways. Related to platelet aggregation.
    Hexanolamino PAF C-16
  • HY-132210
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane 116673-45-1 98%
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane (compound 6) is a platelet-activating factor receptor (PAFR) antagonist with a Ki of 0.3 µM.
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane
  • HY-13221A
    BRL 54443 maleate 1197333-54-2 98%
    BRL 54443 (MALEATE) is a potent 5-HT1E/1F receptor agonist (Ki values are 1.1 nM and 0.7 nM respectively); displays > 30-fold selectivity over other 5-HT and dopamine receptors.
    BRL 54443 maleate
  • HY-132583
    IONIS-DNM2-2.5Rx 2857839-05-3
    IONIS-DNM2-2.5Rx (DYM101) is an antisense agent targeting dynamin 2. IONIS-DNM2-2.5Rx has the potential for the research of centronuclear myopathy (CNM).
    IONIS-DNM2-2.5Rx
  • HY-13289B
    (R)-Nepicastat hydrochloride 195881-94-8 98%
    (R)-Nepicastat hydrochloride is the isomer of Nepicastat (HY-13289). Nepicastat (SYN117) is a selective，potent，and orally active inhibitor of dopamine-beta-hydroxylase. Nepicastat (SYN117) produces concentration-dependent inhibition of bovine (IC50=8.5 nM) and human (IC50=9 nM) dopamine-beta-hydroxylase. Nepicastat (SYN117) can cross the blood-brain barrier (BBB).
    (R)-Nepicastat hydrochloride
  • HY-13295S
    Vinpocetine-d5 2734920-39-7 98%
    Vinpocetine-d5 is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
    Vinpocetine-d5
Cat. No. Product Name / Synonyms Application Reactivity